Long-term maintenance of gp120-specific immune responses by genetic vaccination with the HIV-1 envelope genes linked to the gene encoding Flt-3 ligand

Journal of Immunology

Volumn 170, Issue 5, 2003, Pages 2496-2507

  Sailaja, Gangadhara ^a   Husain, Sajid ^a   Nayak, Bishnu P ^a   Jabbar, Abdul M ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD11 ANTIGEN; CD8 ANTIGEN; DNA VACCINE; ENVELOPE PROTEIN; FLT3 LIGAND; FMS LIKE TYROSINE KINASE RECEPTOR 3; GLYCOPROTEIN GP 120; GROWTH FACTOR; HYBRID PROTEIN; TYROSINE KINASE RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIGEN SPECIFICITY; ARTICLE; CELL DIFFERENTIATION; CELL FUNCTION; CELL PROLIFERATION; CHIMERA; CONTROLLED STUDY; DENDRITIC CELL; ENVELOPE GENE; FEMALE; GENE CONSTRUCT; GENETIC LINKAGE; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNE RESPONSE; IMMUNE SYSTEM; LYMPHOCYTE SUBPOPULATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; VACCINATION;

EID: 0037371125     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.170.5.2496     Document Type: Article

References (73)

1. Akbari, O., N. Panjwani, S. Garcia, R. Tascon, D. Lowrie, and B. Stockinger. 1999. DNA vaccination: transfection and activation of dendritic cells as key events for immunity. J. Exp. Med. 189:169.
2. Condon, C., S. C. Watkins, C. M. Calluzi, K. Thompson, and L. D. Falo, Jr. 1996. DNA-based immunization by in vitro transfection of dendritic cells. Nat. Med. 2:1122.
3. Gurunathan, S., D. M. Klinman, and R. A. Seder. 2000. DNA vaccines: immunology, application, and optimization. Annu. Rev. Immunol. 18:927.
4. + T cells after gene gun immunization. J. Exp. Med. 188:1075.
5. + T cells: cross-priming in infectious diseases. Curr. Opin. Immunol. 13:437.
6. Zingernagel, R. M. 2002. On cross priming of MHC class I-specific CTL: rule or exception. Eur. J. Immunol. 32:2385.
7. Amara, R. R., F. Villinger, J. D. Altman, S. L. Lydy, S. P. O'Neil, S. I. Staprans, D. C. Montefiori, Y. Xu, J. G. Herndon, L. S. Wyatt, et al. 2001. Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine. Science 292:69.
8. Barouch, D. H., S. Santra, J. E. Schmitz, M. J. Kuroda, T. M. Fu, W. Wagner, M. Bilska, A. Craiu, X. X. Zheng, G. R. Krivulka, et al. 2000. Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination. Science 290:486.
9. Letvin, N. L., D. H. Barouch, and D. C. Montefiori. 2002. Prospects for vaccine protection against HIV-1 infection and AIDS. Annu. Rev. Immunol. 20:73.
10. Chakrabarti, B. K., W. P. Kong, B. Y. Wu, Z. Y. Yang, J. Friborg, X. Ling, S. R. King, D. C. Montefiori, and G. J. Nabel. 2002. Modifications of the human immunodeficiency virus envelope glycoprotein enhance immunogenicity for genetic immunization. J. Virol. 76:5357.
11. Mascola, J. R., and G. J. Nabel. 2001. Vaccines for the prevention of HIV-1 disease. Curr. Opin. Immunol. 13:489.
12. + T cell approach feasible? Nat. Rev. Immunol. 2:283.
13. Robinson, H. L. 2002. New hope for an AIDS vaccine. Nat. Rev. Immunol. 2:239.
14. Banchereau, J., and R. M. Steinman. 1998. Dendritic cells and the control of immunity. Nature 392:245.
15. Steinman, R. M., and R. N. Germain. 1998. Antigen presentation and related immunological aspects of HIV-1 vaccines. AIDS 12:S97.
16. Palucka, K., and J. Banchereau. 1999. Linking innate and adaptive immunity. Nat. Med. 5:868.
17. Fay, J. W. 2002. Hematopoietic growth factors, dendritic cell biology, and vaccine therapy of cancer. Curr. Opin. Hematol. 9:202.
18. McKenna, H. J. 2001. Role of hematopoietic growth factors/Flt3 ligand in expansion and regulation of dendritic cells. Curr. Opin. Hematol. 8:149.
19. Pulendran, B., J. Banchereau, E. Maraskovsky, and C. Maliszewski. 2001. Modulating the immune response with dendritic cells and their growth factors. Trends Immunol. 22:41.
20. Banchereau, J., F. Briere, C. Caux, J. Davoust, S. Lebecque S., Y-J. Liu, B. Pulendran, and K. Palucka. 2000. Immunobiology of dendritic cells. Annu. Rev. Immunol. 18:767.
21. Antonysamy, M. A., and A. W. Thomson. 2000. Flt3 ligand (FL) and its influence on immune reactivity. Cytokine 12:87.
22. Lyman, S. D., and S. E. Jacobsen. 1998. c-kit ligand and Flt3 ligand: stem/progenitor cell factors with overlapping yet distinct activities. Blood 91:1101.
23. Maraskovsky, E., K. Brasel, M. Teepe, E. R. Roux, S. D. Lyman, K. Shortman, and H. J. McKenna. 1996. Dramatic increase in the numbers of functionally mature dendritic cells in Flt3 ligand-treated mice: multiple dendritic cell subpopulations identified. J. Exp. Med. 184:1953.
24. Maraskovsky, E., E. Daro, E. Roux, M. Teepe, C. R. Maliszewski, J. Hoek, D. Caron, M. E. Lebsack, and H. J. McKenna. 2000. In vivo generation of human dendritic cell subsets by Flt3 ligand. Blood 96:878.
25. McKenna, H. J., K. L. Stocking, R. E. Miller, K. Brasel, T. De Smedt, E. Maraskovsky, C. R. Maliszewski, D. H. Lynch, J. Smith, B. Pulendran, et al. 2000. Mice lacking Flt3 ligand have deficient hematopoiesis affecting hematopoietic progenitor cells, dendritic cells, and natural killer cells. Blood 95:3489.
26. Pulendran,B., J. Banchereau, S. Burkeholder, E. Kraus, E. Guinet, C. Chalouni, D. Caron, C. Maliszewski, J. Davoust, J. Fay, and K. Palucka. 2000. Flt3-ligand and granulocyte colony-stimulating factor mobilize distinct human dendritic cell subsets in vivo. J. Immunol. 165:566.
27. Pulendran, B., J. L. Smith, G. Caspary, K. Brasel, D. Pettit, E. Maraskovsky, and C. R. Maliszewski. 1999. Distinct dendritic cell subsets differentially regulate the class of immune response in vivo. Proc. Natl. Acad. Sci. USA 96:1036.
28. Gilliet, M., A. Boonstra, C. Paturel, S. Antonenko, X. L. Xu, G. Trinchieri, A. O'Garra, and Y. J. Liu. 2002. The development of murine plasmacytoid dendritic cell precursors is differentially regulated by FLT3-ligand and granulocyte/macrophage colony-stimulating factor. J. Exp. Med. 195:953.
29. Pulendran, B., J. L. Smith, M. Jenkins, M. Schoenborn, E. Maraskovsky, and C. R. Maliszewski. 1998. Prevention of peripheral tolerance by a dendritic cell growth factor: Flt3 ligand as an adjuvant. J. Exp. Med. 188:2075.
30. O'Keeffe, M., H. Hochrein, D. Vremec, J. Pooley, R. Evans, S. Woulfe, and K. Shortman. 2002. Effects of administration of progenipoietin 1, Flt-3 ligand, granulocyte colony-stimulating factor, and pegylated granulocyte- macrophage colony-stimulating factor on dendritic cell subsets in mice. Blood 99:2122.
31. Shortman, K., and Y. J. Liu. 2002. Mouse and human dendritic cell subtypes. Nat. Rev. Immunol. 2:151.
32. + T lymphocytes. J. Virol. 74:4093.
33. Fong, L., Y. Hou, A. Rivas, C. Benike, A. Yuen, G. A. Fisher, M. M. Davis, and E. G. Engleman. 2001. Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumor immunotherapy. Proc. Natl. Acad. Sci. USA 98:8809.
34. Gregory, S. H., A. J. Sagnimeni, N. B. Zurowski, and A. W. Thomson. 2001. Flt3 ligand pretreatment promotes protective immunity to Listeria monocytogenes. Cytokine 13:202.
35. Kremer, I. B., M. P. Gould, K. D. Cooper, and F. P. Heinzel. 2001. Pretreatment with recombinant Flt3 ligand partially protects against progressive cutaneous leishmaniasis in susceptible BALB/c mice. Infect. Immun. 69:673.
36. Merad, M., T. Sugie, E. G. Engleman, and L. Fong. 2002, In vivo manipulation of dendritic cells to induce therapeutic immunity. Blood 99:1676.
37. Moore, A. C., W. P. Kong, B. K. Chakrabarti, and G. J. Nabel. 2002. Effects of antigen and genetic adjuvants on immune responses to human immunodeficiency virus DNA vaccines in mice. J. Virol. 76:243.
38. Parajuli, P., R. L. Mosley, V. Pisarev, J. Chavez, A. Ulrich, M. Varney, R. K. Singh, and J. E. Talmadge. 2001. Flt3 ligand and granulocyte-macrophage colony-stimulating factor preferentially expand and stimulate different dendritic and T-cell subsets. Exp. Hematol. 29:1185.
39. Parajuli, P., V. Pisarev, J. Sublet, A. Steffel, M. Varney, R. Singh, D. LaFace, and J. E. Talmadge. 2001. Immunization with wild-type p53 gene sequences coad-ministered with Flt3 ligand induces an antigen-specific type 1 T-cell response. Cancer Res. 61:8227.
40. Smith, J. R., A. M. Thackray, and R. Bujdoso. 2001. Reduced herpes simplex virus type 1 latency in Flt-3 ligand-treated mice is associated with enhanced numbers of natural killer and dendritic cells. Immunology 102:352.
41. Wu, X., Y. He, L. D. Falo, Jr., K. M. Hui, and L. Huang. 2001. Regression of human mammary adenocarcinoma by systemic administration of a recombinant gene encoding the hFLex-TRAIL fusion protein. Mol. Ther. 3:368.
42. + lymphocyte depletion in rhesus monkeys. J. Virol. 71:4218.
43. Paul, M., and M. A. Jabbar. 1997. Phosphorylation of both phosphoacceptor sites in the HIV-1 Vpu cytoplasmic domain is essential for Vpu-mediated ER degradation of CD4. Virology 232:207.
44. Paul, M., S. Mazumder, N. U. Raja, and M. A. Jabbar. 1998. Mutational analysis of the HIV-1 Vpu transmembrane domain that promotes the enhanced release of virus-like particles (VLPs) from the plasma membrane of mammalian cells. J. Virol. 72:1270.
45. Raja, N. U., and M. A. Jabbar. 1996. The human immunodeficiency virus type 1 Vpu protein tethered to the CD4 extracellular domain is localized to the plasma membrane and is biologically active in the secretory pathway of mammalian cells: implications for the mechanisms of Vpu function. Virology 220:141.
46. He, Y., A. A. Pimenov, J. V. Nayak, J. Plowey, L. D. Falo, Jr., and L. Huang. 2000. Intravenous injection of naked DNA encoding secreted Flt3 ligand dramatically increases the number of dendritic cells and natural killer cells in vivo. Hum. Gene Ther. 11:547.
47. Murali-Krishna, K., J. D. Altman, M. Suresh, D. Sourdive, A. Zajac, J. Miller, J. Slansky, and R. Ahmed. 1998. Counting antigen-specific CD8 cells: a re-evaluation of bystander activation during viral infection. Immunity 8:177.
48. Belyakov, I. M., L. S. Wyatt, J. D. Ahlers, P. Earl, C. D. Pendleton, B. L. Kelsall, W. Strober, B. Moss, and J. A. Berzofsky. 1998. Induction of a mucosal cytotoxic T lymphocyte response by intrarectal immunization with a replication-deficient recombinant vaccinia virus expressing human immunodeficiency virus 89.6 envelope glycoprotein. J. Virol. 72:8264.
49. Takahashi, H., J. Cohen, A. Hosmalin, K. B. Cease, R. Houghten, J. L. Comette, C. DeLisi, B. Moss, R. N. Germain, and J. A. Berzofsky. 1988. An immunodominant epitope of the human immunodeficiency virus envelope glycoprotein gp160 recognized by class I major histocompatibility complex molecule-restricted murine cytotoxic T lymphocytes. Proc. Natl. Acad. Sci. USA 85:3105.
50. Chapman, B. S., R. M. Thayer, K. A. Vincent, and N. L. Haigwood. 1991. Effect of intron A from human cytomegalovirus (Towne) immediate early gene on heterologous expression in mammalian cells. Nucleic Acids Res. 19:3979.
51. Center, R. J., P. L. Eartl, J. Lebowitz, P. Schucvk, and B. Moss. 2000. The human immunodeficiency virus type 1 gp120 V2 domain mediates gp41-independent intersubunit contacts. J. Virol. 74:4448.
52. Binley, J. M., R. W. Sanders, B. Clas, N. Schuelke, A. Master, Y. Guo, F. Kajumo, D. J. Anselma, P. J. Maddon, W. C. Olson, and J. P. Moore. 2000. A recombinant human immunodeficiency virus type 1 envelope glycoprotein complex stabilized by an intermolecular disulfide bond between the gp120 and gp41 subunits is an antigenic mimic of the trimeric virion-associated structure. J. Virol. 74:627.
53. Wyatt, R., and J. Sodroski. 1998. The HIV-1 envelope glycoproteins: fusogens, antigens, and immunogens. Science 280:1884.
54. Yang, X., L. Florin, M. Farzan, P. Kolchinsky, P. D. Kwong, J. Sodroski, and R. Wyatt. 2000. Modifications that stabilize human immunodeficiency virus envelope glycoprotein trimers in solution. J. Virol. 74:4746.
55. Graddis, T. J., K. Brasel, D. Friend, S. Srinivasan, S. Wee, S. D. Lyman, C. J. March, and J. T. McGrew. 1998. Structure-function analysis of FLT3 ligand-FLT3 receptor interactions using a rapid functional screen. J. Biol. Chem. 273:17626.
56. Savvides, S. N., T. Boone, and P. A. Karplus. 2000. Flt3 ligand structure and unexpected commonalities of helical bundles and cystine knots. Nat. Struct. Biol. 7:486.
57. Kaech, S. M., E. J. Wherry, and R. Ahmed. 2002. Effector and memory T-cell differentiation: implications for vaccine development. Nat. Rev. Immunol. 2:251.
58. Jameson, S. C. 2002. Maintaining the norm: T cell homeostasis. Nat. Rev. Immunol. 2:547.
59. Tuma, R. A., and E. G. Pamer. 2002. Homeostasis of naïve, effector and memory CD8 T cells. Curr. Opin. Immunol. 14:348.
60. Hildeman, D. A., Y. Zhu, T. C. Mitchell, J. Kappler, and P. Marrack. 2002. Molecular mechanisms of activated T cell death. Curr. Opin. Immunol. 14:354.
61. McKinney-Freeman, S. L., K. A. Jackson, F. D. Camargo, G. Ferrari, F. Mavilio, and M. A. Goodell. 2002. Muscle-derived hematopoietic stem cells are hematopoietic in origin. Proc. Natl. Acad. Sci. USA 99:1341.
62. Kawada, H., and M. Ogawa. 2001. Bone marrow origin of hematopoietic progenitors and stem cells in murine muscle. Blood 98:2008.
63. Zhang, S., and H. E. Broxmeyer. 2000. Flt3 ligand induces tyrosine phosphorylation of gab1 and gab2 and their association with shp-2, grb2, and PI3 kinase. Biochem. Biophys. Res. Commun. 277:195.
64. Hung, C. F., K. F. Hsu, W. F. Cheng, C. Y. Chai, L. He, M. Ling, and T. C. Wu. 2001. Enhancement of DNA vaccine potency by linkage of antigen gene to a gene encoding the extracellular domain of Fms-like tyrosine kinase 3-ligand. Cancer Res. 61:1080.
65. Biragyn, A., I. M. Belyakov, Y-H. Chow, D. S. Dimitrov, J. A. Berzofsky, and L. W. Kwak. 2002. DNA vaccines encoding human immunodeficiency virus-1 gp120 fusions with proinflammatory chemoattractants induce systemic and mucosal immune responses. Blood 100:1153.
66. Cheng, W. F., C. F. Hung, C. Y. Chai, K. F. Hsu, L. He, M. Ling, and T. C. Wu. 2001. Tumor-specific immunity and antiangiogenesis generated by a DNA vaccine encoding calreticulin linked to a tumor antigen. J. Clin. Invest. 108:669.
67. + T-cell responses: relationship to viral load in untreated HIV infection. J. Virol. 75:11983.
68. + T cell response to human immunodeficiency Gag and Env generated by vaccination with recombinant vesicular stomatitis viruses. J. Virol. 76:2730.
69. + T cells and antiviral protective immunity. J. Virol. 75:9665.
70. Barouch, D. H., A. Craiu, M. J. Kuroda, J. E. Schmitz, X. X. Zheng, S. Santra, J. D. Frost, G. R. Krivulka, M. A. Lifton, C. L. Crabbs, et al. 2000. Augmentation of immune responses to HIV-1 and simian immunodeficiency virus DNA vaccines by IL-2/Ig plasmid administration in rhesus monkeys. Proc. Natl. Acad. Sci. USA 97:4192.
71. + T cell epitope hotspots to exposed strands of HIV envelope glycoprotein suggests structural influences on antigen processing. Proc. Natl. Acad. Sci. USA 98:4587.
72. Ferris, R. L., C. Hall, N. V. Sipsas, J. T. Safrit, A. Trocha, R. A. Koup, R. P. Johnson, and R. F. Siliciano. 1999. Processing of HIV-1 envelope glycoprotein for class I-restricted recognition: dependence on TAP1/2 and mechanisms for cytosolic localization. J. Immunol. 162:1324.
73. Musey, L., J. Hughes, T. Schaker, T. Shea, L. Corey, and M. L. McElrath. 1997. Cytotoxic T cell responses, viral load, and disease progression in early human immunodeficiency virus type 1 infection. N. Engl. J. Med. 337:1267.